Main Menu


A phase II trial of vinflunine chemotherapy in locally advanced and metastatic carcinoma of the penis.

Disease site: Urological cancers

Treatment modality: Systemic therapy (chemotherapy)

Status: Closed

Trial details

VinCaP is a non-randomised, multicentre, phase II trial to determine the clinical benefit and toxicity of vinflunine chemotherapy in patients with inoperable (locally advanced or metastatic) cancer of the penis. The trial will determine whether this drug warrants further research in this patient group.

Twenty-two evaluable patients will be recruited from UK sites over a two-year period to receive vinflunine (320 mg/m2) every 21 days. Four cycles will be administered prior to formal restaging of disease. Patients with clinical benefit will continue on treatment until disease progression or until toxicity supervenes, or until treatment is discontinued according to clinician or patient decision. Patients will be followed up for a maximum of 24 months.

Further information

Chief Investigator: Dr Lisa Pickering, St George’s Healthcare NHS Trust

Clinical Co-ordinator: Dr Steve Nicholson, Consultant in Medical Oncology, & International Study Chair, International Rare Cancers Initiative in Penile Cancer

ICR-CTSU Statistical Lead: Dr Emma Hall

Trial management contact: [email protected]

Sponsor: The Institute of Cancer Research

View VinCaP on the National Institute for Health Research website: NIHR - Be Part Of Research

Patient friendly information is available from Cancer Research UK

Publications and presentations

There have been no presentations or publications to date.

Clinical trials

Division of Clinical Studies

The division carries out or coordinates high-quality trials and translational research at both an early phase – typically to test new targeted drugs – and a later stage.